ReviewTheranostics2025
Phenylboronic acid in targeted cancer therapy and diagnosis.
Review in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A γ-Ray-Responsive Dynamic Covalent Polymeric Radioprotectant for Efficient Radiation Injury Treatment.Advanced healthcare materials · 2026Article
- Research advances in intelligent microenvironment-responsive hydrogels for myocardial infarction therapy.APL bioengineering · 2026Review
- Glucose-responsive "sense-and-treat" microneedle patch for promoting diabetic chronic wound healing.Materials today. Bio · 2026Article
- Tumor-targeted liposomal RNAi therapy suppresses breast cancer and modulates tumor microenvironment.Journal of nanobiotechnology · 2026Article
- Small-Molecule Boron-10-Enriched Carriers with Exceptional Aqueous Solubility for Enhanced Boron Neutron Capture Therapy of Malignant Tumors.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few decades, phenylboronic acid (PBA) and its derivatives have gained attention for their biological activity. More recently, they have gained interest for their application in targeted cancer therapy, owing to their ability to selectively and reversibly bind to sialic acids on the cell surface through the formation of boron ester bonds. Initially, the research was focused on the antitumor properties of simple PBA derivatives. However, it has since expanded to include more complex nanomaterials and drug-delivery systems that exploit the unique properties of PBA for enhanced therapeutic efficacy. This paper presents a comprehensive review of the physico-chemical background of PBA-based drugs in cancer therapy, provides insight into recent advancements in PBA-based systems for targeted drug delivery and their role in improving antitumor efficacy, and offers a perspective on future research and development in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.